Louisiana State University

LSU Digital Commons
Faculty Publications

Department of Physics & Astronomy

8-21-2011

Investigation of dose perturbations and the radiographic visibility
of potential fiducials for proton radiation therapy of the prostate
Jessie Y. Huang
University of Texas Graduate School of Biomedical Sciences at Houston

Wayne D. Newhauser
University of Texas Graduate School of Biomedical Sciences at Houston

X. Ronald Zhu
University of Texas Health Science Center at Houston

Andrew K. Lee
University of Texas Health Science Center at Houston

Rajat J. Kudchadker
University of Texas Graduate School of Biomedical Sciences at Houston

Follow this and additional works at: https://digitalcommons.lsu.edu/physics_astronomy_pubs

Recommended Citation
Huang, J., Newhauser, W., Zhu, X., Lee, A., & Kudchadker, R. (2011). Investigation of dose perturbations
and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate. Physics in
Medicine and Biology, 56 (16), 5287-5302. https://doi.org/10.1088/0031-9155/56/16/014

This Article is brought to you for free and open access by the Department of Physics & Astronomy at LSU Digital
Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital
Commons. For more information, please contact ir@lsu.edu.

NIH Public Access
Author Manuscript
Phys Med Biol. Author manuscript; available in PMC 2012 August 21.

NIH-PA Author Manuscript

Published in final edited form as:
Phys Med Biol. 2011 August 21; 56(16): 5287–5302. doi:10.1088/0031-9155/56/16/014.

Investigation of dose perturbations and radiographic visibility of
potential fiducials for proton radiation therapy of the prostate
Jessie Y. Huang1,2, Wayne D. Newhauser1,3, X. Ronald Zhu3, Andrew K. Lee4, and Rajat J.
Kudchadker1,3
1The University of Texas at Houston Graduate School of Biomedical Sciences, 6767 Bertner
Avenue, S3.8344, Houston, TX 77030, USA
2Department

of Imaging Physics, The University of Texas MD Anderson Cancer Center, 1515
Holcombe Boulevard, Unit 193, Houston, TX 77030, USA
3Department

of Radiation Physics, The University of Texas MD Anderson Cancer Center, 1515
Holcombe Boulevard, Unit 94, Houston, TX 77030, USA

NIH-PA Author Manuscript

4Department

of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515
Holcombe Boulevard, Houston, TX 77030, USA

Abstract
Image guidance using implanted fiducial markers is commonly used to ensure accurate and
reproducible target positioning in radiation therapy for prostate cancer. The ideal fiducial marker
is clearly visible in kV imaging, does not perturb the therapeutic dose in the target volume, and
does not cause any artifacts on the CT images used for treatment planning. As yet, ideal markers
that fully meet all three of these criteria have not been reported. In this study, twelve fiducial
markers were evaluated for their potential clinical utility in proton radiation therapy for prostate
cancer. In order to identify the good candidates, each fiducial was imaged using a CT scanner as
well as a kV imaging system. Additionally, the dose perturbation caused by each fiducial was
quantified using radiochromic film and a clinical proton beam. Based on the results, three fiducials
were identified as good candidates for use in proton radiotherapy of prostate cancer.
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1. Introduction
Advances in radiation therapy have led to an increase in the conformality of modern
treatments. With increasingly conformal treatment options, such as 3-D conformal
radiotherapy (3D-CRT), intensity modulated radiotherapy (IMRT), and proton therapy, dose
escalation is possible while simultaneously decreasing margins around the target volume and
thus reducing normal tissue toxicities. For prostate therapy, increased dose to the tumor is
associated with better outcomes (Fuller and Scarbrough, 2006). However, decreased margins
necessitate more accurate and reproducible patient positioning and target alignment. For
prostate radiation therapy, target alignment is complicated by internal movement of the
prostate within the pelvis (Nederveen et al., 2003) caused by variations in bladder and rectal
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filling (Kupelian et al., 2005). Several strategies have been employed to overcome these
positioning problems, including use of rectal balloons, daily CT scans, urethral catheters,
transabdominal ultrasonography, and image-guided radiotherapy (IGRT) using implanted
fiducial markers (Welsh et al., 2004). Serago et al., (2006) showed that target positioning
with the use of kilovoltage (kV) imaging of fiducial markers was more consistent with
electronic portal imaging (EPI) than positioning based on ultrasound, the most common
alternate method to implanted fiducial markers for prostate positioning. IGRT with fiducial
markers has recently become the state of the art in external beam prostate radiotherapy. In
fiducial marker-based IGRT, daily radiographic images reveal the position of the markers,
enabling precise alignment of the target with the treatment beam (Hsu et al., 2007).
However, a disadvantage of this technique is that implanted fiducial markers perturb the
radiation beam and cause downstream dose shadows in both a photon beam (Chow and
Grigorov, 2005) and a proton beam (Newhauser et al., 2007a; Newhauser et al., 2007b;
Ptaszkiewicz et al., 2010; Giebeler et al., 2009). Furthermore, fiducial markers made of
high-Z (atomic number) materials, such as gold, can also cause significant streak artifacts on
computed tomography (CT) images that are used for treatment planning. These potential
drawbacks must be taken into account when choosing a fiducial marker for prostate therapy
and weighed against the benefits of superior target positioning. For proton therapy of
prostate cancer, the ideal fiducial marker is visible in kV images used for daily alignment,
causes no dose perturbations in a proton beam, and causes no streak or void artifacts on CT
images (Cheung et al., 2010). Ideal fiducial markers that meet all three of these criteria do
not currently exist. However, many candidate markers are available for evaluation to
determine if they are clinically acceptable, if not perfect in all respects. In this study, a total
of twelve fiducial markers of different shapes, sizes, and material compositions were
evaluated along these criteria as potential candidates for use in proton radiation therapy of
the prostate.

2. Methods and Materials
2.1 Fiducials
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One of the twelve fiducial markers is a barbell-shaped fiducial (Carbon Medical
Technologies, Inc, St. Paul, Minnesota) composed of a proprietary ZrO2 core coated with a
outer layer of carbon (BiomarC®), which is currently in clinical use at The University of
Texas M. D. Anderson Cancer Center for prostate localization in patients receiving proton
therapy. The remaining eleven fiducials are prototype fiducials (Carbon Medical
Technologies, Inc) with shapes, material compositions, and dimensions listed in Table 1.
The dimensions and mass of each fiducial were measured and crosschecked against
specifications from the manufacturer and were used to estimate the average density of each
fiducial.
2.2 Radiographic visibility
The radiographic visibility of the fiducials was assessed by acquiring CT images and kV
radiographic images of the fiducials in a pelvic anthropomorphic phantom (RANDO®, The
Phantom Laboratory, Salem, NY). The section of the phantom that was imaged was
approximately 27 cm in the AP direction and 40 cm in the lateral direction. The fiducials
were placed inside plastic tubes that fit snuggly into specially drilled holes in the phantom
and were backfilled with tissue-equivalent bolus material in order to avoid artifacts caused
by air gaps. CT images of the phantom were acquired using a 16-slice scanner (GE
Healthcare, Waukesha, WI) with a pelvis scanning protocol (120 kVp, 250 mAs, 2.5 mm
slice thickness, 1.27 mm pixel spacing). kV images were acquired using a kV on-board
imaging (OBI) system on an electron linear accelerator (Clinac 21EX linear accelerator,
Varian Medical, Palo Alto, CA) at our institution with the following techniques:120 kVp,
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200 mA, and 630 ms for lateral images and 75 kVp, 200 mA, and 80 ms for AP images. For
each kV image, a single fiducial was inserted into the phantom at the approximate location
of the prostate in order to closely mimic a patient with an implanted fiducial marker. Setup
images of patients are typically acquired in orthogonal pairs just prior to treatment. Thus in
our study, we imaged the phantom using kV x-rays at orthogonal cardinal angles (0 degrees
and 90 degrees or 0 degrees and 270 degrees).
2.3 Quantification of CT streak artifacts
The artifacts caused by each fiducial were quantified by analyzing the CT images of the
fiducials inside the pelvic phantom. For each fiducial, a ring-shaped region of interest (ROI)
was defined; this ROI was centered at the position of the fiducial and included the area
between an inner radius of 4 pixels and an outer radius of 10 pixels. This ROI was chosen to
include the streak artifacts that emanate radially outward from the fiducial and to exclude
fiducial itself. A streak index for quantifying the streak artifacts was defined as
, where HUmax and HUmin are the maximum and minimum CT
numbers inside the ROI and σ(HU)true is the standard deviation of the CT numbers in 20
pixels in a homogenous region of the phantom that was free of any streak artifact. SI is a
metric used for quantifying the severity of streak artifacts and is similar to the index
employed by Imai et al (2009).
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2.4 Dose Perturbation Measurements
2.4.1 Proton Beam—In order to quantify the dose shadows caused by each fiducial in a
proton beam, measurements were performed using the commercial treatment system
(Probeat; Hitachi Ltd., Tokyo, Japan) at our institution (Newhauser et al., 2007b). The
treatment setup was chosen to closely mimic an actual prostate treatment. For these
measurements, we used a 225 MeV passively-scattered proton beam with a range in water of
26.9 cm and a spread out Bragg peak (SOBP) of 10 cm. The system used was a fixed-beam
system with a small size snout, which contained a 10 cm × 10 cm final collimating aperture
made of brass.
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2.4.2 Radiochromic Film—Proton absorbed dose was measured using radiochromic film
(Gafchromic EBT2, lots F04090903 and F08130902A; International Specialty Products,
Wayne, NJ). The films were digitized using a flatbed scanner (Expression 10000XL, Epson,
Long Beach, CA) in landscape orientation into 48-bit color images at a spatial resolution of
72 dpi. The films were scanned prior to irradiation in order to obtain the background optical
density and then scanned approximately 72 hours following irradiation. In order to convert
net optical density to absorbed dose, a calibration curve was created by irradiating film at a
water-equivalent depth of 21 cm to absorbed doses ranging from 1 Gy to 6 Gy. A separate
calibration curve was prepared for each lot of film. The suitability of radiochromic film for
proton beam dose measurements has been previously documented (Daftari et al., 1999;
Vatnitsky, 1997; Niroomand-Rad et al., 1998; Piermattei et al., 2000; Butson et al., 2003;
Soares, 2006).
2.4.3 Phantom Setup and Irradiation—In order to measure the maximum dose
perturbation caused by each fiducial, a small (12 × 6 × 3.5 cm3) polymethyl methacrylate
(PMMA) phantom was used; the phantom consists of a stack of 1 mm slabs of PMMA
mounted together with nylon nuts and screws to form a block. The fiducials and
radiochromic films were sandwiched between the PMMA slabs. The phantom was
mechanically compressed to minimize air gaps. The twelve fiducials were split into two
batches of six fiducials each. For each batch, the fiducials were implanted in a polystyrene
foam board and oriented with the long axis of the fiducial perpendicular to the direction of
Phys Med Biol. Author manuscript; available in PMC 2012 August 21.
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the beam; the entire board was then sandwiched into the PMMA phantom. Measurements
were taken with the fiducials located at water-equivalent depths in the phantom of 22.2 cm
(approximately middle of the SOBP) and 25.7 cm (near the end of range of the proton
beam). For each fiducial implantation depth, radiochromic films were placed distal to the
fiducials in 1 mm increments (1.157 mm water equivalent thickness (WET)) in order to
study the effects of dose perturbation as a function of distance downstream from the
fiducial; twelve films were used for each fiducial implantation depth. Only three films were
sandwiched into the phantom for each irradiation in order to minimize the range shift caused
by the film.
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2.4.4 Radiochromic Film Analysis of Dose Perturbations—The digitized images of
the radiochromic films were analyzed using public domain image processing software
(ImageJ, National Institute of Health, Bethesda, MD). In order to quantify the dose
perturbation caused by the presence of a particular fiducial, optical transmission values at
the location of the fiducial were compared to a reference transmission value, which was
obtained from an unperturbed region of the same film. Transmission values were averaged
over different areas depending on the size of the fiducial under study: 3×3 pixels (1.06 ×1.06
mm2) for spherical fiducials, 5×3 pixels (1.76 ×1.06 mm2) for ZrO2/Pebax® polymer
fiducials, 5×5 pixels (1.76 ×1.76 mm2) for unperturbed reference and background
measurements, and 5×2 pixels (1.76 ×0.71 mm2) for all other fiducials. Sample pieces of
film are shown in Figure 1 to illustrate this process. These average transmission values were
then used to calculate the net optical density and relative proton absorbed dose.
2.4.5 Physical Analysis of Dose Perturbations—In order to better understand why
certain fiducials cause greater dose perturbations when placed in the path of a clinical proton
beam, we tested for correlations between dose and proton linear stopping power and
is proportional to . Therefore, the
scattering power. The proton linear stopping power
amount of energy dE lost by a proton when it travels through a fiducial is approximately
proportional to

, where ρt is the mass thickness of the fiducial along the direction of the

beam. The change in the characteristic scattering angle per path length traveled

is

(Newhauser et al., 2007b). Therefore, the change in characteristic
proportional to
scattering angle caused by a particular fiducial dθRMS is approximately proportional to
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. These equations were used to estimate the dE and dθRMS caused by each fiducial in
order to understand the relationship between these quantities and the resulting dose
perturbations. Based on the material compositions reported by the manufacturer, effective
values for the atomic number Zeff and atomic mass Aeff of each fiducial were used in these
estimates. Please note that only very rough estimates of Zeff and Aeff were used in the
calculations for the PEKK polymer because its chemical composition is proprietary;
however, Zeff and Aeff are very similar for almost all plastics. The strength of any linear
correlations found was quantified by calculating the correlation coefficient (r2 value).

3. Results
3.1 Physical characteristics of fiducials
A brief description of the material composition, shape, and size of each fiducial in this study
is listed in Table 1, and photographs of all the fiducials are shown in Figure 2. The fiducials
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will henceforth be referred to by the fiducial names given in the first column of Table 1.
Table 2 lists the mass m, the physical thickness t, and the mass thickness ρt of each fiducial.
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3.2 Radiographic Visibility
Lateral and AP kV images of the fiducial markers inside the anthropomorphic phantom are
shown in Figures 2 and 3, respectively. For the lateral kV images, the 40% ZrO2 polymer
rod and the 20% BaSO4/PEKK polymer tube were not visible, and the long C-coated ZrO2 3
bump rod was faint but still discernible; remainder of the fiducials were clearly visible. For
the AP kV images, all of the fiducials were clearly visible except for the 20% BaSO4/PEKK
polymer tube, which was faint but still discernible. For the CT images of the pelvic
phantom, all the fiducials were clearly visible except for the 20% BaSO4/PEKK polymer
tube. Although the radiographic visibility of the thick carbon-coated ZrO2 rod on CT images
was not verified, since all of the other carbon-coated ZrO2 fiducials were clearly visible, it is
a fair assumption that the thick carbon-coated ZrO2 rod would also be visible on CT images.
The results of all radiographic visibility tests are summarized in Table 1.
3.3 Quantification of Streak Artifacts

NIH-PA Author Manuscript

Based on a comparison of the calculated values of the streak index SI, the C-coated W rod
and C-coated Pt rod caused the greatest streak artifacts while the long C-coated ZrO2 3
bump rod caused the least streak artifacts (Table 1). This quantitative result agrees with a
visual assessment of the CT images since the streaks caused by the C-coated W rod and Ccoated Pt rod are clearly visible (Figure 4a) compared to the other fiducials which caused
minimal streak artifacts (Figure 4b).
3.4 Dose Perturbation Measurements
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The relative dose perturbation (ΔD) is plotted as a function of distance downstream of the
fiducial for implantation depths of 22.2 cm and 25.7 cm WET (Figures 5 and 6), and the
maximum dose perturbation (ΔDmax) caused by each fiducial at both implantation depths is
listed in Table 2. In general, the dose perturbations were greater when the fiducials were
placed near the end of the proton beam’s range (25.7 cm) compared to the middle of the
SOBP (22.2 cm), which is consistent with previous studies (Cheung et al., 2010; Newhauser
et al., 2007a; Newhauser et al., 2007b). For fiducials located at 22.2 cm (middle of the
SOBP), there was no distance downstream of the fiducials where there was a clear
maximum in the magnitude of ΔD (Figure 3). At this implantation depth, the ΔDmax for each
fiducial ranged from 4% to 18%, and all of the fiducials except the C-coated W rod and Pt
fiducials had a %ΔDmax of less than 10% (Table 2). For the measurements taken with the
fiducials placed approximately 1 cm from the end of the proton’s range (25.7 cm), dose
perturbations were reported only for points downstream of the fiducial that fell confidently
within the SOBP of the proton beam in order to avoid the large dose gradients at the end of
the proton beam’s range. The ΔD increased steadily until the end of the proton range was
reached for fiducials at this implantation depth (Figure 4), and the ΔDmax caused by each
fiducial ranged from 3% to 47%. Only the small C-coated ZrO2 sphere, the thin C-coated
ZrO2 rod, the C-coated ZrO2 3 bump rod, and the 20% BaSO4 /PEKK polymer tube had a
ΔDmax ≤ 10% at this implantation depth (Table 2).
In Figure 7, the ΔDmax caused by each fiducial at implantation depths of 22.2 cm and 25.7
cm is plotted against estimates of the decrease in energy dE and the change in characteristic
scattering angle dθRMS of a proton as it travels through that fiducial.
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In order to assess the clinical utility of several prototype fiducials for proton therapy of the
prostate, we evaluated each fiducial marker based on three criteria: radiographic visibility in
kV portal images, CT streak artifacts, and perturbations of proton absorbed dose. In the
radiographic imaging portion of this study, the 20% BaSO4 /PEKK polymer tube and the
40% ZrO2 polymer rod , both of which had low densities compared to the other fiducial
markers (0.88 and 1.4 g/cm3 respectively),were the only fiducial markers that were not
visible in kV lateral portal images. This result suggests that there is a correlation between
the mass density of the fiducial and its radiographic visibility in kV portal imaging, and that
for a given marker size and imaging technique, there is a minimum density required for a
fiducial to be clearly visible.
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Various metrics have been proposed to quantify the severity of streak artifacts on CT
images. Van der Schaaf et al (2006) quantified metal streak artifacts caused by surgical clips
with the volume of artifact and the number of white radiating streaks. Leng et al (2008)
defined the total variation (TV) of the CT image as a figure of merit to quantify streaking
artifacts. Imai et al (2009) employed the largest difference between adjacent CT values for
line profiles that were placed almost perpendicular to streak artifacts as an index for
measuring streak artifacts. In this study, we adapted Imai’s index in order to quantify the
severity of radial streaks instead of parallel streaks and defined our own streak index SI, the
largest difference between CT values in a ring-shaped region of interest surrounding a
fiducial marker, normalized by the standard deviation of CT values in a homogenous region
free of streak artifacts. The difference beween our index SI and Imai’s index is that a ringshaped ROI is used instead of a rectangular one and that our index is normalized by the
standard deviation of CT number is a homogenous region near the ROI. This quantitative
method of calculating SI agreed well with qualitative results (i.e. a visual assessment of CT
images) and seems to be well-suited for this specific application, evaluating the severity of
radial streak artifacts on CT images caused by fiducial markers. Furthermore, this streak
index allows for easy, quantitative comparison between different fiducial markers, and
opens up the possibility to more accurately assess and optimize the size, shape, and material
design of fiducial markers.
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When the streak artifacts caused by individual fiducials in CT images were quantified using
our streak index SI, the C-coated W (Z=74) and Pt (Z=78) rod fiducials caused the greatest
streak artifacts. These artifacts are caused by high-Z, high density metals, which results in
incomplete attenuation profiles (Barrett and Keat, 2004). Because streak artifacts in CT
images of the patient can interfere with target delineation and cause errors in dose and range
calculations in the treatment planning system, these results suggest that high density, high-Z
metals should be avoided if possible when choosing the material composition for a fiducial
marker.
The dose reduction caused by each fiducial was measured using radiochromic film. Based
on a clinical tolerance level of 10 % dose reduction, several fiducials markers were
eliminated as potentially suitable candidates. The rationale for this 10 % clinical tolerance
level for dose heterogeneity has been justified elsewhere (Newhauser et al., 2007a) and is
based on previous studies that have shown that dose perturbations of approximately 10 % do
not adversely affect clinical outcomes for prostate cancer treatment. In this study, all
fiducials were oriented perpendicular to the beam direction, the orientation which represents
the best case scenario in terms of the dosimetric impact of the fiducials. Fiducials oriented
parallel to the proton beam will have a greater mass thickness and thus will cause greater
dose shadows. Cheung et al. (2010) reported a 38% dose perturbation for a carbon-coated
ZrO2 fiducial in the parallel orientation compared to 18% for perpendicular orientation. For
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this reason, physicians try to implant fiducials in the perpendicular orientation at our
institution. Our results also showed that dose perturbations increased by as much as 30%
when the fiducial was placed near the end of range as opposed to the center of modulation;
this result agrees with previous studies that suggest that implantation at the periphery of the
target volume should be avoided (Cheung et al., 2010; Giebeler et al., 2009; Newhauser et
al., 2007a). Whether or not the dose reductions near the end of range are clinically relevant
depends on the fiducial implantation protocol followed by each individual institution. At our
institution, two fiducial markers are implanted per patient, one in the base of the prostate and
one in the contra-lateral apex of the prostate. The rationale behind this choice of fiducial
number and location is based on our previous work that has shown that this specific
combination of fiducials rivals the use of three fiducials in terms of accuracy of prostate
alignment while minimizing the effects of CT artifacts and proton dose shadowing
(Kudchadker et al., 2009). Furthermore, lateral margins are maintained so that the large dose
gradients near the end of range of the proton beam are avoided. Thus, the end of range dose
perturbations are not clinically relevant for the protocol followed at our institution.
However, for institutions that do implant fiducials close to the periphery of the prostate (or
liver) for proton therapy, the dose heterogeneities near the end of range should be kept
≤10% as well. Based on our analysis of the dose perturbation data, a positive correlation was
found between the magnitude of the dose perturbation and the mass thickness, proton linear
stopping power, and proton linear scattering power of a fiducial. These results suggest that a
thin fiducial with low density and low atomic number will cause smaller dose perturbations
in a proton beam.
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Although each of the criteria (radiographic visibility, CT streak artifacts, and dose
perturbations) was evaluated separately in this study, it is important to note that these criteria
are not independent of each other. Photoelectric absorption is a dominant interaction for
photons in the diagnostic imaging energy range (kV), and the probability of interaction via
photoelectric absorption is proportional to cube of the atomic number, i.e., Z3. Therefore,
fiducials made of higher Z materials will be more easily seen in kV diagnostic images.
Furthermore, more photon attenuation will occur for fiducials with greater mass thickness
(ρt). Therefore, thick, dense fiducials composed of high-Z materials will exhibit greater
contrast in kV radiographs and will thus be more easily visible using this imaging modality.
On the other hand, high-Z, high density materials will cause greater streak artifacts in CT
images as well as greater proton dose perturbations. It is clear from the results of this study,
that the best fiducial marker designs involve compromises between competing criteria;
specifically, designing the optimal fiducial marker requires balancing radiographic visibility
against streak artifacts and dose perturbations. Importantly, new results from this work
suggest that the three performance criteria used to evaluate the fiducials can be quantified
(e.g. by using the proposed streak index), and that the proton dose perturbations can be
modeled with simple, semi-empirical relations that depend on the material’s Z, ρ, and t.
Together, for the first time, the streak index and semi-empirical dose relationships make
possible the mathematical statement of a single figure of merit, i.e., an objective function
suitable for use with an optimization algorithm. Future work involving Monte Carlo
simulations could be used to optimize material composition, shape, and dimensions of
fiducials based on this figure of merit without the need to fabricate every prototype fiducial
of interest.
A major strength of this study is that we evaluated and compared twelve fiducials, including
one in clinical use at our institution, with various shapes, sizes, and material compositions,
based on several clinically relevant criteria. Although other studies have been done
involving fiducial marker visibility in kV imaging and dose perturbations caused by markers
in a proton beam, there have not been any studies involving such a variety of fiducials
markers or a study in which the CT streak artifacts caused by the fiducials was assessed
Phys Med Biol. Author manuscript; available in PMC 2012 August 21.
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quantitatively along with the radiographic visibility and dose perturbations (Lim et al.,
2009). A limitation of this study is that the visibility of the fiducials was verified for kV Xrays and CT only, and not for other imaging modalities that can be used in IGRT, such as
MRI and ultrasound. Although MV portal imaging was not a focus in this study, we did
image the fiducials in the anthropomorphic phantom using this imaging modality. With the
lower contrast of MV imaging, only the C-coated W and C-coated Pt fiducials were clearly
visible inside the phantom. Although we agree that MV imaging is an important aspect of
photon radiotherapy setup verification and that visibility in MV imaging would greatly
expand the usefulness of these fiducial markers, our study is focused on the use of fiducials
for proton therapy and thus, the fact that the majority of the markers were not visible in MV
imaging is not an issue. Furthermore, another limitation of this study is that dose shadow
measurements were taken with the fiducials in two separate batches. It would be preferable
to load all the fiducials into the phantom and irradiate them at the same time, eliminating
any slight variations in beam output and phantom orientation, compression, or position that
might exist between the two batches. However, the physical size of the phantom prohibited
loading all twelve fiducials at once; the dose measurement for a fiducial could potentially be
perturbed by neighboring fiducials due to the close proximity of the fiducials in this
arrangement. Thus, the fiducials were split into two batches to avoid any interactions
between fiducials. An additional limitation of this study is that although the fiducials were
imaged in tubes containing tissue equivalent bolus in order to closely mimic a fiducial
marker implanted in a patient, it is possible that small air gaps were present in between the
fiducial and the phantom. These air gaps, though small, could be a source of error in our SI
calculations.
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Based on the results of this study, carbon-coated ZrO2 (Zeff = 56) would be a judicious
choice for fiducial material because this material represents a good compromise between
radiographic visibility and dose perturbations; its Zeff is not as high as some of the metals in
this study, such as platinum or tungsten, and it will therefore not cause such severe streak
artifacts or dose perturbations. Furthermore, all of the carbon-coated ZrO2 fiducials in this
study were visible in kV images. However, the 40% ZrO2/Pebax® polymer rod was faint
compared to the other fiducials in both AP and lateral kV images, suggesting that a
minimum percentage of ZrO2 needs to be present in the fiducial to ensure good radiographic
visibility. (Henry et al., 2005) investigated the optimal length and diameter of gold
cylindrical fiducial markers for radiotherapy verification using electronic portal imaging, but
there has not been a study on the optimal size, shape, and mass thickness of carbon-coated
ZrO2 fiducials. In particular, the minimum mass thickness of a carbon-coated ZrO2 required
for maintaining good visibility would be of interest since thinner fiducials cause lower dose
perturbations. The general recommendations that can be extracted from this study (mid-Z
material, minimize mass thickness while maintaining good radiographic visibility) as well as
the proposed figure of merit can be applied to the design of more exotic fiducials, such as
strings of fiducial markers on a bio-absorbable strand or coiled fiducials (Fuller and
Scarbrough, 2006), as well as novel applications of fiducials, such as implanting fiducial
markers along with source seeds for image guidance in prostate brachytherapy followed by
external beam radiation (Welsh et al., 2004).

5. Conclusions
In this study, twelve fiducial markers, eleven of which are prototype fiducials and one that is
routinely used clinically at our institution, were evaluated to determine their suitability for
use in proton therapy of prostate cancer. The best fiducial markers were radiographically
visible in kV portal images, caused minimal streak artifacts in CT images, and caused
minimal dose perturbations when placed in a proton beam (≤10%). Based on the results of
our experiments, three of the prototype fiducials (the small C-coated ZrO2 sphere, the thin
Phys Med Biol. Author manuscript; available in PMC 2012 August 21.
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C-coated ZrO2 rod, and the C-coated ZrO2 3 bump rod) met all of these criteria and were
deemed excellent candidates for application in proton therapy of the prostate. However, the
requirements of a fiducial marker used for proton therapy depends on the specific
application as well as the implantation protocols (i.e. the location and number of markers
implanted). Thus, each institution must evaluate this data in the context of its specific needs.
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Figure 1.

Digitized images of radiochromic film (one from each batch of fiducials irradiated). Both
films were irradiated near the end of proton range. Transmission values were averaged over
the rectangular pixel regions shown.
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Figure 2.

kV lateral images (120 kVp, 200 mA, 630 ms) of fiducial markers inside an
anthropomorphic phantom. Blown up insets of the kV images along with photographs of the
fiducials themselves are shown for a) C-coated ZrO2 barbell, b) small C-coated ZrO2 sphere,
c) large C-coated ZrO2 sphere, d) thin C-coated ZrO2 rod, e) thick C-coated ZrO2 rod, f)
40% ZrO2 polymer rod, g) 80% ZrO2 polymer rod, h) C-coated ZrO2 3 bump rod, i) long Ccoated ZrO2 3 bump rod, j) C-coated W rod, k) C-coated Pt rod, and l) 20% BaSO4/PEKK
polymer tube.
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Figure 3.

AP lateral images (75 kVp, 200 mA, 80 ms) of fiducial markers inside an anthropomorphic
phantom. Blown up insets are shown for a) C-coated ZrO2 barbell, b) small C-coated ZrO2
sphere, c) large C-coated ZrO2 sphere, d) thin C-coated ZrO2 rod, e) thick C-coated ZrO2
rod, f) 40% ZrO2 polymer rod, g) 80% ZrO2 polymer rod, h) C-coated ZrO2 3 bump rod, i)
long C-coated ZrO2 3 bump rod, j) C-coated W rod, k) C-coated Pt rod, and l) 20% BaSO4/
PEKK polymer tube.
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Figure 4.
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CT slice image (120 kVp, 250 mAs, 2.5 mm slice thickness, 1.2695 mm pixel spacing)
demonstrating (a) clearly visible streak artifacts due to the C-coated W rod (center) and
carbon coated Pt (bottom right) fiducials and (b) minimal streak artifacts due to the C-coated
ZrO2 barbell (top right), the C-coated ZrO2 3 bump rod (center), and the long C-coated ZrO2
3 bump rod (bottom left).
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Figure 5.

Dose perturbation relative to the unperturbed dose as a function of distance downstream of
the fiducial at an implantation depth of 22.2 cm WET, which corresponds to approximately
the middle of the SOBP. Please note that these results are reported on two separate plots
because the measurements were performed separately for two batches of fiducials (six in
each batch) due to the limited size of the phantom used for dose measurements.
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Figure 6.

Dose perturbation relative to the unperturbed dose as a function of distance downstream of
the fiducial at an implantation depth of 25.7 cm WET, which corresponds to approximately
1 cm upstream of the end of range of the proton beam. Note that these results are reported on
two separate plots because the measurements were performed separately for two batches of
fiducials (six in each batch) due to the limited size of the phantom used for dose
measurements.
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Figure 7.

The maximum percentage of dose perturbation caused by each fiducial at two depths (22.2
cm and 25.7 cm) plotted against estimates of the decrease in proton energy (a) and the
change in the characteristic scattering angle (b).
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Barbell-shaped, BiomarC® carboncoated ZrO2
carbon-coated ZrO2 sphere with 1 mm
diameter
carbon-coated ZrO2 sphere with 1.5
mm diameter
carbon-coated ZrO2 rod with 0.69 mm
core diameter and 0.94 total diameter
carbon-coated ZrO2 rod with 0.69 mm
core diameter and 1.26 total diameter
Cylindrical shape, composite material
with 40% ZrO2 and 60% Pebax®
polymer
Cylindrical shape, composite material
with 80% ZrO2 and 20% Pebax®
polymer
carbon-coated ZrO2 rod with 3 bumps,
0.69 mm core diameter and 1.26 total
diameter
Longer carbon-coated ZrO2 rod with 3
bumps, 0.69 mm core diameter and
1.26 total diameter
Carbon-coated tungsten rod
Carbon-coated platinum rod, 0.69 mm
core diameter and 1.26 total diameter
Cylindrical tube with pores,
composite material with 20% BaSO4
and 80% 35 poly(ether ketone ketone)
(PEKK) polymer

C-coated ZrO2 barbell

small C-coated ZrO2 sphere

large C-coated ZrO2 sphere

thin C-coated ZrO2 rod

thick C-coated ZrO2 rod

40% ZrO2 polymer rod

80% ZrO2 polymer rod

C-coated ZrO2 3 bump rod

long C-coated ZrO2 3 bump
rod

C-coated W rod

C-coated Pt rod

20% BaSO4/PEKK polymer
tube

no

yes

yes

faint

yes

yes

no

yes

yes

yes

yes

yes

faint

yes

yes

yes

yes

yes

yes

yes

yes

yes

yes

yes

no

yes

yes

yes

yes

yes

yes

n/aa

yes

yes

yes

yes

n/ab

42.1

34.0

5.8

8.2

12.6

7.4

n/aa

9.1

8.9

9.1

13.4

SI

CT

kV
lateral

kV
AP

Streak
Artifacts

Radiographic
visibility

The 20% BaSO4/PEKK polymer tube was excluded from the CT streak artifact quantification portion of this study because it was not visible on CT images of the pelvic phantom.

b

The thick C-coated ZrO2 rod was excluded from the CT streak artifact quantification portion of this study because it was temporarily misplaced.

a

Description

Fiducial name

Summary of the results for the radiographic visibility and CT streak artifact quantification studies for all twelve fiducials.
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6
<1
7
3
8
13
20
9
12
50
47
5

small C-coated ZrO2 sphere

large C-coated ZrO2 sphere

thin C-coated ZrO2 rod

thick C-coated ZrO2 rod

40% ZrO2 polymer rod

80% ZrO2 polymer rod

C-coated ZrO2 3 bump rod

long C-coated ZrO2 3 bump rod

C-coated W rod

C-coated Pt rod

20% BaSO4/PEKK polymer tube

m
(mg)

C-coated ZrO2 barbell

Fiducial name

0.88

12.0

14.3

2.4

2.5

2.6

1.4

2.3

1.7

3.2

1.3

5.9

ρ
(g/cm3)

0.62

1.17

1.01

1.09

1.17

1.79

1.91

1.17

0.87

1.61

1.15

0.77

t
(mm)

0.05

1.40

1.44

0.26

0.30

0.46

0.27

0.26

0.15

0.51

0.14

0.45

ρt
(g/cm2)

−13
−7
−22
−10
−15
−20
−31
−10
−13
−47
−47
−3

−5
−7
−4
−4
−5
−9
−5
−2
−16
−18
−4

25.7 cm
depth

−4

22.2 cm
depth

ΔDmax (%)

Summary of the physical characteristics of each fiducial (mass m, density ρ, thickness t, mass thickness ρt) and percent maximum dose perturbation %
ΔDmax at two implantation depths, 22.2 cm and 25.7cm. The thickness listed is the maximum thickness along the direction of the proton beam and
depends on the orientation of the fiducial during irradiation.
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